Page 189 - 2021_04-Haematologica-web

LH suppression and hematopoietic recovery
myeloid leukemia or high-risk myelodys- plastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106(5):1090-1098.
5. Wang Y, Probin V, Zhou D. Cancer thera- py-induced residual bone marrow injury- Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2(3):271-279.
6.Shao L, Wang Y, Chang J, et al. Hematopoietic stem cell senescence and cancer therapy-induced long-term bone marrow injury. Transl Cancer Res. 2013;2(5):397-411.
7. Mierzejewska K, Borkowska S, Suszynska E, et al. Hematopoietic stem/progenitor cells express several functional sex hor- mone receptors-novel evidence for a poten- tial developmental link between hematopoiesis and primordial germ cells. Stem Cells Dev. 2015;24(8):927-937.
8. Abdelbaset-Ismail A, Suszynska M, Borkowska S, et al. Human haematopoietic stem/progenitor cells express several func- tional sex hormone receptors. J Cell Mol Med. 2016;20(1):134-146.
9.Velardi E, Tsai JJ, Radtke S, et al. Suppression of luteinizing hormone enhances HSC recovery after hematopoiet- ic injury. Nat Med. 2018;24(2):239-246.
10. Khong DM, Dudakov JA, Hammett MV, et al. Enhanced hematopoietic stem cell func- tion mediates immune regeneration follow- ing sex steroid blockade. Stem Cell Reports. 2015;4(3):445-458.
11. Dudakov JA, Goldberg GL, Reiseger JJ, et al. Sex steroid ablation enhances hematopoietic recovery following cytotox- ic antineoplastic therapy in aged mice. J Immunol. 2009;183(11):7084-7094.
12. Quaas AM, Ginsburg ES. Prevention and treatment of uterine bleeding in hemato- logic malignancy. Eur J Obstet Gynecol Reprod Biol. 2007;134(1):3-8.
13. Jadoul P, Kim SS, Committee IP. Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet. 2012;29(6):479-487.
14. Poorvu PD, Barton SE, Duncan CN, et al. Use and effectiveness of gonadotropin- releasing hormone agonists for prophylac- tic menstrual suppression in postmenarchal women who undergo hematopoietic cell transplantation. J Pediatr Adolesc Gynecol. 2016;29(3):265-268.
15. Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for paramet- ric causal inference. J Stat Software. 2011; 42(8):1-28.
16. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Association. 1979;74(368):829-
836.
17. Liang KY, Zeger SL. Longitudinal data
2019;15(6):785-794.
29.Nichols CR, Roth BJ, Heerema N, et al.
Hematologic neoplasia associated with pri- mary mediastinal germ-cell tumors. N Engl J Med. 1990;322(20):1425-1429.
30. Hartmann JrT, Fossa SD, Nichols CR, et al. Incidence of metachronous testicular can- cer in patients with extragonadal germ cell tumors. J Natl Cancer Inst. 2001; 93(22):1733-1738.
31. Nichols CR, Hoffman R, Einhorn LH, et al. Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med. 1985;102(5):603-609.
32. Taylor J, Donoghue MTA, Ho C, et al. Germ cell tumors and associated hemato- logic malignancies evolve from a common shared precursor. J Clin Invest. 2020;130 (12):6668-6676.
33.Goldberg GL, King CG, Nejat RA, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allo- geneic bone marrow transplantation. J Immunol. 2009;182(9):5846-5854.
34. Ataya KM, McKanna JA, Weintraub AM, et al. A luteinizing hormone-releasing hor- mone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985;45(8):3651- 3656.
35. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in pre- menopausal women undergoing chemotherapy for early-stage breast can- cer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(1):65-73.
36. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update. J Clin Oncol. 2018;36(19):1994-2001.
37.Nakada D, Oguro H, Levi BP, et al. Oestrogen increases haematopoietic stem- cell self-renewal in females and during pregnancy. Nature. 2014;505(7484):555- 558.
38. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532-1542.
39.Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299-312.
40. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and rec- ommendations. Nat Rev Drug Discov. 2019;18(1):41-58.
41. Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017; 18(1):100-111.
18.
19.
20.
analysis using generalized linear models. Biometrika. 1986;73(1):13-22.
Jabbour E, Short NJ, Ravandi F, et al. A ran- domized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017;123(22):4430-4439.
Nazha A, Kantarjian H, Ravandi F, et al. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients </=60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013;88(11):961-966.
Jain P, Kantarjian HM, Ravandi F, et al. Cladribine combined with idarubicin and Ara-C (CLIA) as frontline and salvage treat- ment for young patients (≤65 yrs) with acute myeloid leukemia. Blood. 2016; 128(22):1639-1639.
21. Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experi- ence with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016;91(8):819-823.
22. Shao L, Sun Y, Zhang Z, et al. Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation. Blood. 2010; 115(23):4707-4714.
23. Yu H, Shen H, Yuan Y, et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood. 2010;115(17):3472-3480.
24. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1319-1339.
25.Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118-1129.
26. Walter D, Lier A, Geiselhart A, et al. Exit from dormancy provokes DNA-damage- induced attrition in haematopoietic stem cells. Nature. 2015;520(7548):549-552.
27. Fabiani E, Falconi G, Fianchi L, et al. Clonal evolution in therapy-related neoplasms. Oncotarget. 2017;8(7):12031-12040.
28. Bujko K, Cymer M, Adamiak M, et al. An overview of novel unconventional mecha- nisms of hematopoietic development and regulators of hematopoiesis - a roadmap for future investigations. Stem Cell Rev Rep.
haematologica | 2021; 106(4)
1105